Fusions with receptor tyrosine kinase genes (such as ALK, ROS1, NTRK, and MET) are highly prevalent and preclinical studies show promising results for kinase inhibitors for this glioma type [10,45,47]. The gene discussed is MET; the disease is central nervous system cancer.